peregrine danno hold ...
report recente .. prossimo a metà marzo
ultimo commento del 22/01/2014
Peregrine Pharmaceuticals, Inc. (PPHM - Snapshot Report) was a big mover last session, as its shares rose almost 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up over 33% in the past one-month timeframe.
In the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Peregrine currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked stocks in the medical sector include Gentium S.p.A (GENT - Snapshot Report), Emergent BioSolutions, Inc. (EBS - Snapshot Report) and Actelion Ltd. (ALIOF). All three sport a Zacks Rank #1 (Strong Buy).